Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.35 |
| ▸ | INPPL1 | O15357 | 6/20 | 0.33 |
| ▸ | INPP5A | Q14642 | 3/20 | 0.33 |
| ▸ | INPP5B | P32019 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6399417 | 0.91 | ESR1 (0.36) | ESR1ESR2INPPL1INPP5AINPP5B | |
| SCHEMBL6397248 | 0.89 | INPPL1 (0.33) | INPPL1INPP5AINPP5BMIFKDM4E | |
| SCHEMBL6397769 | 0.84 | ESR1 (0.34) | ESR1ESR2INPPL1INPP5AINPP5B | |
| SCHEMBL6404041 | 0.82 | INPPL1 (0.33) | ESR1ESR2INPPL1INPP5AINPP5B | |
| SCHEMBL6398379 | 0.82 | INPPL1 (0.37) | ESR1ESR2INPPL1INPP5AINPP5B | |
| SCHEMBL6402017 | 0.82 | ESR1 (0.38) | ESR1ESR2MIFPDCD1CD274 | |
| SCHEMBL6401196 | 0.79 | ESR1 (0.38) | ESR1ESR2MIFPDCD1CD274 | |
| SCHEMBL6397316 | 0.79 | INPPL1 (0.38) | ESR1ESR2INPPL1INPP5AINPP5B | |
| SCHEMBL6401094 | 0.78 | INPPL1 (0.38) | ESR1ESR2INPPL1INPP5AINPP5B | |
| SCHEMBL6396076 | 0.78 | CYP2C9 (0.37) | ESR1ESR2INPPL1INPP5AINPP5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187195-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | PEERCE BRIAN E (US) | 2005-08-25 | — | — | US | disclosed |
| US-6787528-B2 | THERAPY FOR KIDNEY DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-09-07 | — | — | US | disclosed |
| US-20030162753-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-08-28 | — | — | US | disclosed |
| US-20020133036-A1 | Inhibitors of intestinal apical membrane Na/phosphate co-transportation | PEERCE BRIAN E (US) | 2002-09-19 | — | — | US | disclosed |
| US-6355823-B1 | MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187195-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | SLC34A3, SLC34A1, SLC34A2 | ESR1 2885/4885ESR2 2416/4885INPPL1 82/4885 |
| US-20020133036-A1 | Inhibitors of intestinal apical membrane Na/phosphate co-transportation | SLC10A2, SLC34A3, SLC34A1 | ESR1 3212/4885ESR2 2699/4885INPPL1 85/4885 |
| US-20030162753-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | SLC34A3, SLC34A1, SLC34A2 | ESR1 2885/4885ESR2 2416/4885INPPL1 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.